These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22956183)

  • 21. Incomplete DJH rearrangements.
    González D; Garcia-Sanz R
    Methods Mol Med; 2005; 113():165-73. PubMed ID: 15968101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.
    O'Reilly J; Meyer B; Baker D; Herrmann R; Cannell P; Davies J
    Leukemia; 1995 Apr; 9(4):624-7. PubMed ID: 7723395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
    Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
    Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
    Tousková M; Maisnar V; Krejsek J; Kopecký O
    Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.
    van der Velden VH; Brüggemann M; Hoogeveen PG; de Bie M; Hart PG; Raff T; Pfeifer H; Lüschen S; Szczepański T; van Wering ER; Kneba M; van Dongen JJ
    Leukemia; 2004 Dec; 18(12):1971-80. PubMed ID: 15470492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
    Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
    Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases.
    Hadzidimitriou A; Stamatopoulos K; Belessi C; Lalayianni C; Stavroyianni N; Smilevska T; Hatzi K; Laoutaris N; Anagnostopoulos A; Kollia P; Fassas A
    Haematologica; 2006 Jun; 91(6):781-7. PubMed ID: 16769580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
    Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
    J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved.
    Ouspenskaia MV; Johnston DA; Roberts WM; Estrov Z; Zipf TF
    Leukemia; 1995 Feb; 9(2):321-8. PubMed ID: 7869771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
    Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
    Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
    Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
    Yata K; Yaccoby S
    Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
    Martinez-Lopez J; Lahuerta JJ; Pepin F; González M; Barrio S; Ayala R; Puig N; Montalban MA; Paiva B; Weng L; Jiménez C; Sopena M; Moorhead M; Cedena T; Rapado I; Mateos MV; Rosiñol L; Oriol A; Blanchard MJ; Martínez R; Bladé J; San Miguel J; Faham M; García-Sanz R
    Blood; 2014 May; 123(20):3073-9. PubMed ID: 24646471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.